Life Cycle Investment Partners Ltd Makes New $35.02 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Life Cycle Investment Partners Ltd bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 88,076 shares of the biopharmaceutical company’s stock, valued at approximately $35,023,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $36,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $39,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the transaction, the executive vice president directly owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 6,799 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the transaction, the chief executive officer directly owned 98,628 shares in the company, valued at $32,315,464.20. The trade was a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,255 shares of company stock valued at $6,930,337 in the last three months. 0.86% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Royal Bank Of Canada dropped their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $297.45 on Friday. The firm’s 50 day simple moving average is $311.16 and its 200-day simple moving average is $359.49. The company has a market cap of $39.71 billion, a P/E ratio of 81.27 and a beta of 0.31. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $284.19 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.44) earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.